Fig. 1: IL-33 induces PD-1 expression in pulmonary ILC2s.
From: PD-1 pathway regulates ILC2 metabolism and PD-1 agonist treatment ameliorates airway hyperreactivity
a Pulmonary ILC2s were defined and/or sorted by a lack of lineage markers (CD3e, CD45R, Gr-1, CD11c, CD11b, Ter119, CD5, TCR-β, TCR-γδ, NK1.1, and FcɛRI) and expression of CD45, ST2, and CD127. b–j BALB/cByJ mice (WT) mice were challenged or not (naïve) with 0.5 μg of rm-IL-33 for 3 consecutive days. ILC2s from IL-33-challenged mice were defined as activated (aILC2s). b Representative histogram of the expression of PD-1, c PDL-1, and d PDL-2 in pulmonary ILC2s and corresponding quantification (right) presented as Mean Fluorescence Intensity (MFI); n = 5. e Gating strategy to define PD-L1 and PD-L2 live positive cells from f CD45+ and i CD45− cells in IL-33 challenged mice. g, h Percentage of PD-L2+ and/or PD-L1+ cells from CD45+ and j CD45− cells; n = 4. Data are representative of three independent experiments and are presented as means ± SEM (two-tailed Student’s t test, n.s. non-significant).
